Australia markets closed

IGC Pharma, Inc. (IGC)

NYSE American - Nasdaq Real-time price. Currency in USD
Add to watchlist
0.4701-0.0060 (-1.26%)
As of 02:51PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 31.45M
Enterprise value 30.45M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)21.94
Price/book (mrq)3.47
Enterprise value/revenue 25.04
Enterprise value/EBITDA -2.76

Trading information

Stock price history

Beta (5Y monthly) 1.77
52-week change 333.33%
S&P500 52-week change 321.23%
52-week high 30.9100
52-week low 30.2500
50-day moving average 30.3934
200-day moving average 30.3419

Share statistics

Avg vol (3-month) 3956.67k
Avg vol (10-day) 31.75M
Shares outstanding 566.06M
Implied shares outstanding 666.81M
Float 856.96M
% held by insiders 120.44%
% held by institutions 13.71%
Shares short (28 Mar 2024) 4938.8k
Short ratio (28 Mar 2024) 41.25
Short % of float (28 Mar 2024) 41.50%
Short % of shares outstanding (28 Mar 2024) 41.42%
Shares short (prior month 29 Feb 2024) 4910.73k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:10
Last split date 319 Apr 2013

Financial highlights

Fiscal year

Fiscal year ends 31 Mar 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-1,469.61%

Management effectiveness

Return on assets (ttm)-44.01%
Return on equity (ttm)-103.36%

Income statement

Revenue (ttm)1.22M
Revenue per share (ttm)0.02
Quarterly revenue growth (yoy)-38.60%
Gross profit (ttm)N/A
EBITDA -10.4M
Net income avi to common (ttm)-14.14M
Diluted EPS (ttm)-0.2600
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.38M
Total cash per share (mrq)0.02
Total debt (mrq)380k
Total debt/equity (mrq)4.20%
Current ratio (mrq)1.85
Book value per share (mrq)0.14

Cash flow statement

Operating cash flow (ttm)-6.19M
Levered free cash flow (ttm)-1.91M